CompletedPhase 4

A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).

Brazil493 participantsStarted 2011-03

Plain-language summary

The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * chronic statin use * positive stress test findings (electrocardiography, nuclear imaging, or stress echocardiography * elective angioplasty. Exclusion Criteria: * non-statin therapy * any presentation of ACS within 24 hours before the time of randomization * current use of potent CYP3A4 inhibitors, including azole antifungals, protease inhibitors, macrolide antibiotics, and cyclosporine * renal replacement therapy, a history of kidney transplant, pregnant and with renal failure (serum creatinine \> 3.0 mg/dl).

What they're measuring

Contrast induce nephropathy defined by serum creatinine increase more than 0.3mg/dl or 50% higher than baseline

Timeframe: 48 hours

Trial details

NCT IDNCT02737319

SponsorUniversity of Sao Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-12

View on ClinicalTrials.gov More Nephropathy trials